Recent Updates
Recently added Catalysts
XTNT Positive Sentiment

Xtant Medical Wins Auction for Surgalign’s Hardware and Biologics Business

Friday, July 28, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xtant Medical Holdings, Inc. has successfully acquired Surgalign's hardware and biologics business, a strategic move aimed at enhancing its spinal fusion devices portfolio. This acquisition is expected to strengthen Xtant's market position in the medical technology sector focused on surgical solutions for spinal disorders. The announcement was made on July 28, 2023.
Price reaction · baseline $0.875 (2023-07-28T19:47:00.000Z) · hit during market hours · 2 other XTNT headline(s) in the window, move may be shared
day 0 close · peak
-2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Xtant Medical expands its portfolio through acquisition.
  • The acquisition enhances their spinal fusion devices offerings.
  • Strategic move to strengthen market position.

Full Press Release Details

Acquisition to Enhance Xtant’s Growing Spinal Fusion Devices Portfolio BELGRADE, Mont. , July 28, 2023 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced

Frequently Asked Questions

What did Xtant Medical acquire?

Xtant Medical acquired Surgalign's hardware and biologics business.

Why is the acquisition significant?

The acquisition enhances Xtant's portfolio in spinal fusion devices.

When was the acquisition announced?

The acquisition was announced on July 28, 2023.

What is Xtant Medical focused on?

Xtant Medical focuses on surgical solutions for spinal disorders.

ShareAdd on Google
Tags: XTNT Viatris Investor Conferences Healthcare Xtant Medical Surgalign spinal fusion medical technology
Last updated: Jul 28, 2023

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~4 mo
High dilution risk